期刊文献+

利培酮和奥氮平长疗程治疗对女性精神分裂症患者血清催乳素的影响 被引量:24

在线阅读 下载PDF
导出
摘要 目的 比较利培酮和奥氮平1年期疗程对首发生殖期女性精神分裂症患者催乳素的影响。方法 80例年龄18~44岁的首发女性精神分裂症患者按随机数字表法分为利培酮组和奥氮平组,每组各40例,利培酮组给予利培酮(4.6±0.6) mg,奥氮平组给予奥氮平片(14.2±5.2) mg,进行为期12个月的研究。于治疗前、治疗后第1,3,6,9,12个月末测定血清催乳素浓度,并使用阳性与阴性症状量表(PANSS)对精神症状进行评定。结果 利培酮组有32例完成研究,奥氮平组有34例。相同治疗时点两组PANSS量表评分差异无统计学意义(均P〉0.05);利培酮组治疗后各时点血清催乳素浓度均高于奥氮平组,两者差异有统计学意义(均P〈0.01),利培酮组高催乳素血症发生率均高于奥氮平组,两组间差异有统计学意义(均P〈0.01)。结论 利培酮长程治疗比奥氮平对患者血清催乳素影响更大。
作者 江斌 史克银
出处 《医药导报》 CAS 2016年第10期1079-1081,共3页 Herald of Medicine
  • 相关文献

参考文献7

  • 1SUZUKI Y, SUGAI T, FUKUI N, et al. Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics [ J ].Sehizophr Res,2013,145(]-3) : 116- 119.
  • 2ASMAL L, FLEGAR S J, WANG J, et al. Qiletiapine versus other atypical antipsychotics for schizophrenia [ J ]. Cochrane Database Syst Rev, 2013 ( 11 ) : CD006625.
  • 3KRZYSTANEK M, KRUPKA-MATUSZCZYK I. An open, large,6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine [ J ]. Hum Psychopharmacol, 2011,26 ( 1 ) : 81- 85.
  • 4房茂胜,赵靖平,国效峰,翟金国,陆铮,孙学礼,王传跃,谢世平,胡斌,郭田生,马崔,汪波,吕路线,刘娜,邓红,陈琦,尚晓芳,龚发金,张喜艳,何小林,周建初,张迎黎.七种抗精神病药对精神分裂症患者维持治疗一年的有效性及安全性研究[J].中华精神科杂志,2009,42(1):1-6. 被引量:11
  • 5WANG L J, REE S C, HUANG Y S, et al. Adjunctive effects of aripiprazole on metabolic profiles:comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs [ J ]. Prog Neuropsychopnarmacol Bid Psychiatry, 2013,40: 260-266.
  • 6ROERIG J L, STEFFEN K J, MITCHELL J E.Atypical anti- psychotic-induced weight gain: insights into mechanisms of action[J] .CNS Drugs,2011,25(12) : 1035-1059.
  • 7HEAL D J, GOSDEN J, JACKSON H C, et al. Metabolic consequences of antipsychotic therapy:preclinical and clinical perspectives on diabetes, diabetic ketoacidosis, and obesity [ J] .Handb Exp Pharmacol, 2012,212:135-164.

二级参考文献14

  • 1昂秋青,张明园.停药率和停药前用药时间是抗精神病药长期效应的重要评估指标[J].中华精神科杂志,2007,40(1):1-4. 被引量:18
  • 2Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry, 2005, 10: 79-104.
  • 3Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry, 2003, 60 : 553 -564.
  • 4I.eucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet, 2003, 361 : 1581-1589.
  • 5Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry, 2003, 160:1209-1222.
  • 6Thomas P. The stable patient with schizophrenia-from antipsychotic effectiveness to adherence. Eur Neruopsychopharmacol, 2007,17 Suppl 2 : S115-S122.
  • 7Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 2005, 353 : 1209-1223.
  • 8American Psychiatric Association. Diagnasitc and statistical manual of mental disorders. 4th ed. DSM-IV. Washington : APA, 1994:273-292.
  • 9Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull, 1987, 13:261-267.
  • 10Csemansky JG, Mahmoud R, Brenner R, et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med, 2002,346:16-22.

共引文献10

同被引文献189

二级引证文献180

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部